Journal
LABORATORY INVESTIGATION
Volume 90, Issue 6, Pages 940-952Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/labinvest.2010.58
Keywords
anticancer therapy; CAMEL peptide; combined therapy; immunotherapy; necrosis
Categories
Funding
- Polish Ministry of Science and Higher Education [3P05A 161 29, NN401 034736]
Ask authors/readers for more resources
This study analyzed whether therapy with CAMEL, an antimicrobial peptide (KWKLFKKIGAVLKVL), possess anticancer benefits. Although the peptide was cytotoxic for all the cell lines tested, it did not cause hemolysis, which suggests that CAMEL does not damage cell membranes. After cellular internalization, CAMEL localized to mitochondria and lowered the mitochondrial potential, resulting in the organelles' swelling, a decrease in cellular ATP level and, finally, cellular breakdown. High mobility group box 1 (HMGB1) protein, a necrotic death marker, was shown to be released from cells treated with CAMEL. Growth of B16-F10 melanoma tumors was clearly restrained after injections with CAMEL and could be kept in check throughout the period of peptide administration. However, if therapy was stopped, tumors started to grow again 3-4 days later. To reduce tumor volume and block tumor relapse, a combined therapy was required involving CAMEL and plasmid DNA carrying the interleukin-12 (IL-12) gene. The two therapeutic agents used in combination (a series of CAMEL injections first, followed by daily administration of plasmid DNA) delayed tumor growth and extended survival of treated animals in a statistically significant manner. Complete tumor regression was found in 60% of cases. Laboratory Investigation (2010) 90, 940-952; doi:10.1038/labinvest.2010.58; published online 8 March 2010
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available